Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.

Sridar C, Snider NT, Hollenberg PF.

Drug Metab Dispos. 2011 May;39(5):782-8. doi: 10.1124/dmd.110.036707. Epub 2011 Feb 2.

2.

The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.

Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, Hollenberg PF.

J Pharmacol Exp Ther. 2008 Nov;327(2):538-45. doi: 10.1124/jpet.108.141796. Epub 2008 Aug 12.

3.

Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.

Snider NT, Walker VJ, Hollenberg PF.

Pharmacol Rev. 2010 Mar;62(1):136-54. doi: 10.1124/pr.109.001081. Epub 2010 Feb 4. Review.

4.

A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.

Snider NT, Nast JA, Tesmer LA, Hollenberg PF.

Mol Pharmacol. 2009 Apr;75(4):965-72. doi: 10.1124/mol.108.053439. Epub 2009 Jan 26.

5.

Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides.

Snider NT, Kornilov AM, Kent UM, Hollenberg PF.

J Pharmacol Exp Ther. 2007 May;321(2):590-7. Epub 2007 Feb 1.

6.

Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.

Cravatt BF, Lichtman AH.

Curr Opin Chem Biol. 2003 Aug;7(4):469-75. Review.

PMID:
12941421
8.

Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, Felder CC.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):407-23. Epub 2006 May 31.

PMID:
16736384
9.

Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.

Holt S, Paylor B, Boldrup L, Alajakku K, Vandevoorde S, Sundström A, Cocco MT, Onnis V, Fowler CJ.

Eur J Pharmacol. 2007 Jun 22;565(1-3):26-36. Epub 2007 Mar 7.

PMID:
17397826
10.
11.

Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.

Walker VJ, Griffin AP, Hammar DK, Hollenberg PF.

J Pharmacol Exp Ther. 2016 Jun;357(3):537-44. doi: 10.1124/jpet.116.232553. Epub 2016 Mar 21.

12.

Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.

Castelli MP, Paola Piras A, D'Agostino A, Pibiri F, Perra S, Gessa GL, Maccarrone M, Pistis M.

Eur J Pharmacol. 2007 Nov 14;573(1-3):11-9. Epub 2007 Jul 4.

PMID:
17644084
13.

Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.

Haller VL, Stevens DL, Welch SP.

Eur J Pharmacol. 2008 Dec 14;600(1-3):50-8. doi: 10.1016/j.ejphar.2008.08.005. Epub 2008 Aug 20.

PMID:
18762181
14.

Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.

Glaser ST, Deutsch DG, Studholme KM, Zimov S, Yazulla S.

Vis Neurosci. 2005 Nov-Dec;22(6):693-705.

PMID:
16469181
15.

Temporal and spatial distribution of the cannabinoid receptors (CB1, CB2) and fatty acid amide hydroxylase in the rat ovary.

Bagavandoss P, Grimshaw S.

Anat Rec (Hoboken). 2010 Aug;293(8):1425-32. doi: 10.1002/ar.21181.

16.

Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists.

Pascual AC, Martín-Moreno AM, Giusto NM, de Ceballos ML, Pasquaré SJ.

Exp Gerontol. 2014 Dec;60:92-9. doi: 10.1016/j.exger.2014.10.011. Epub 2014 Oct 18.

PMID:
25456842
17.

The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption.

Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, Torella M, Santoro C, Nobili B, Perrotta S, Di Marzo V, Maione S.

Bone. 2009 Mar;44(3):476-84. doi: 10.1016/j.bone.2008.10.056. Epub 2008 Nov 14.

PMID:
19059369
18.

FAAH and anandamide: is 2-AG really the odd one out?

Di Marzo V, Maccarrone M.

Trends Pharmacol Sci. 2008 May;29(5):229-33. doi: 10.1016/j.tips.2008.03.001. Epub 2008 Apr 18.

PMID:
18394720
19.

Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey.

Kawahara H, Drew GM, Christie MJ, Vaughan CW.

Br J Pharmacol. 2011 Jul;163(6):1214-22. doi: 10.1111/j.1476-5381.2010.01157.x.

20.

The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.

Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, Mikics E, Haller J, Yasar S, Tanda G, Goldberg SR.

Neuropharmacology. 2008 Jan;54(1):129-40. Epub 2007 Aug 19.

Supplemental Content

Support Center